Top

International Journal of Clinical Oncology

Published in:

01-06-2017 | Original Article

Preoperative platelet–lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Authors: Tiffany Sin Hui Bong, Grace Hwei Ching Tan, Claramae Chia, Khee Chee Soo, Melissa Ching Ching Teo

Published in: International Journal of Clinical Oncology | Issue 3/2017

Abstract

Objective

The aim of this study was to examine the prognostic significance of preoperative inflammatory-based indices, platelet–lymphocyte ratio (PLR), neutrophil–lymphocyte ratio (NLR), and carcinoembryonic antigen (CEA) in predicting overall survival (OS) in patients with colorectal peritoneal carcinomatosis (CPC) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods

Sixty patients with pathologically confirmed CPC treated with CRS and HIPEC between 2003 and 2015 were included. Levels of preoperative PLR, NLR, and CEA were recorded. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS.

Results

Median OS was 36 months (95% CI, 26.6–45.4) and 5-year OS was 40.5% (95% CI, 27.3–51.6%). Preoperative PLR (p = 0.034) and CEA (p = 0.036) were found to be significant prognostic markers of OS, whereas NLR did not affect OS. PLR remained significant on multivariate analysis (hazard ratio, 1.035; 95% CI, 1.027–1.043; p < 0.001).

Conclusion

Our study indicates that preoperative PLR may be used as a prognostic marker in CPC patients undergoing CRS and HIPEC and could be useful in the preoperative setting when selecting patients for surgery. The subset of patients with PLR > 300 have a median OS of 5 months (95% CI, 0–24.6 months), indicating that CRS and HIPEC may not be superior to systemic chemotherapy in this subset of patients.

Lemmens V et al (2010) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:2717–2725CrossRefPubMed

Segelman J et al (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705CrossRefPubMed

Chua T, Liauw W, Chu F, Morris D (2012) Viewing metastatic colorectal cancer as a curable chronic disease. Am J Clin Oncol 35:77–80CrossRefPubMed

Klaver Y et al (2012) Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol (EJSO) 38:617–623CrossRef

Franko J et al (2011) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–267CrossRefPubMedPubMedCentral

Verwaal V (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743CrossRefPubMed

Franko J, Ibrahim Z, Gusani N et al (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer (Phila) 116(16):3756–3762CrossRef

Randle R et al (2014) Peritoneal surface disease with synchronous hepatic involvement treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 22:1634–1638CrossRefPubMedPubMedCentral

Saxena A, Yan T, Morris D (2009) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 34:70–78CrossRef

10.

Kwakman R, Schrama A, van Olmen J et al (2016) Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases. Ann Surg 263(6):1102–1111. doi:10.1097/sla.0000000000001593 CrossRefPubMed

11.

Baumgartner J et al (2014) Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 22:1716–1721CrossRefPubMed

12.

Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68. doi:10.1200/jco.2009.23.9285 CrossRefPubMed

13.

Nikolic S et al (2014) Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience. Eur J Surg Oncol (EJSO) 40:S163CrossRef

14.

Sluiter NR, de Cuba EMS, Kwakman R, et al (2016) Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Clin Exp Metastasis 33:297–307

15.

de Cuba E, de Hingh IHJT, Sluiter NR, et al (2016) Angiogenesis-related markers and prognosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Ann Surg Oncol 23:1601–1608

16.

Szkandera J, Pichler M, Absenger G et al (2014) The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 208(2):210–214CrossRefPubMed

17.

Choi W, Cleghorn M, Jiang H et al (2015) Preoperative neutrophil-to-lymphocyte ratio is a better prognostic serum biomarker than platelet-to-lymphocyte ratio in patients undergoing resection for nonmetastatic colorectal cancer. Ann Surg Oncol 22(S3):603–613CrossRef

18.

Roxburgh C, McMillan D (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1):149–163CrossRefPubMed

19.

Ding P, An X, Zhang R et al (2010) Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 25(12):1427–1433CrossRefPubMed

20.

Mallappa S, Sinha A, Gupta S et al (2011) Pre-operative neutrophil lymphocyte ratio greater than 5 is a prognostic factor for recurrent colorectal cancer. Int J Surg 9(7):495CrossRef

21.

He W, Yin C, Guo G et al (2011) Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 30(1)

22.

Sugarbaker P (1995) Peritonectomy procedures. Ann Surg 221:29–42CrossRefPubMedPubMedCentral

23.

Jacquet P, Sugarbaker P (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374CrossRefPubMed

24.

Zhou X et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 9:e101119CrossRefPubMedPubMedCentral

25.

Glehen O et al (2004) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91:747–754CrossRefPubMed

26.

Glehen O (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292CrossRefPubMed

27.

Shen P et al (2004) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11:178–186CrossRefPubMed

28.

Royal R, Pingpank J (2008) Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol 35:183–191CrossRefPubMed

29.

Verwaal V, van Tinteren H, van Ruth S, Zoetmulder F (2004) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739–746CrossRefPubMed

30.

Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 15:49–58

31.

Pelz J, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J (2009) Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 99:9–15CrossRefPubMed

32.

Gilly F, Carry P, Sayag A, Brachet A (1994) Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41:124–129PubMed

33.

Ng J, Ong W, Chia C et al (2016) Prognostic relevance of the peritoneal surface disease severity score compared to the peritoneal cancer index for colorectal peritoneal carcinomatosis. Int J Surg Oncol (article ID 24951311–7)

34.

Templeton A, Ace O, McNamara M et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(7):1204–1212CrossRef

35.

He W, Yin C, Guo G et al (2013) Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 30(1):439CrossRefPubMed

36.

Szkandera J et al (2014) The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 208:210–214CrossRefPubMed

37.

Kwon H, Kim S, Oh S et al (2012) Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17(3):216–222CrossRefPubMed

38.

Terauchi M, Kajiyama H, Yamashita M, Kato M et al (2007) Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis 24(5):329–339CrossRefPubMed

39.

Kokenyesi R, Murray K, Benshushan A et al (2003) Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cells’ matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol 89(1):60–72CrossRefPubMed

40.

Pocard M, Debruyne P, Bras-Gonasalves R et al (2001) Single alteration of p53 or E-cadherin genes can alter the surgical resection benefit in an experimental model of colon cancer. Dis Colon Rectum 44(8):1106–1112CrossRefPubMed

41.

Meyers M (1973) Distribution of intra-abdominal malignant seeding: dependency of dynamics of flow of ascitic fluid. Invest Radiol 8(4):289CrossRef

42.

Jonjic N (1992) Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 176(4):1165–1174CrossRefPubMed

43.

Bittinger F, Klein C, Skarke C et al (1996) PECAM-1 expression in human mesothelial cells: an in vitro study. Pathobiology 64(6):320–327CrossRefPubMed

44.

Radziwon-Balicka A, Medina C, O’Driscoll L et al (2012) Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol 167(4):787–804CrossRefPubMedPubMedCentral

45.

Battinelli E, Markens B, Italiano J (2011) Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118(5):1359–1369CrossRefPubMedPubMedCentral

46.

Gay L, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2):123–134CrossRefPubMed

47.

Gasic G, Gasic T, Stewart C (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61(1):46–52CrossRefPubMedPubMedCentral

48.

Nieswandt B, Hafner M, Echtenacher B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59(6):1295–1300PubMed

49.

Seo A, Lee H, Kim E et al (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109(10):2705–2713CrossRefPubMedPubMedCentral

50.

Fogar P, Sperti C, Basso D et al (2006) Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32(1):22–28CrossRefPubMed

51.

Esquivel J, Sugarbaker PH (1998) Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed. Cancer Ther 1:321–325

Title: Preoperative platelet–lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Authors: Tiffany Sin Hui Bong
Grace Hwei Ching Tan
Claramae Chia
Khee Chee Soo
Melissa Ching Ching Teo
Publication date: 01-06-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1092-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer

Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma

Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer

Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy

Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer